Tolerability of ADXS11-001 Lm-LLO Listeria Based Immunotherapy With Mitomycin, Fluorouracil and Radiation for Anal Cancer

ADXS11-0011 Lm-LLO is a live attenuated Listeria monocytogenes (Lm) bacterium bioengineered to secrete the HPV-16 E7 protein fused with a truncated fragment of listeriolysin O (tLLO) that preferentially infects antigen-presenting cells. Exposure to ADXS11-001 may stimulate T-cells to target HPV-transformed cells. The objective of this study was to obtain safety and preliminary efficacy data of the combination of ADXS11-001 with mitomycin, FU and intensity modulated radiation therapy (IMRT) in locally advanced anal cancer.

http://ift.tt/2rm624R